Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
A phase 2 trial of Ibritumomab tiuxetan and Rituximab in Non-Hodgkin lymphoma, run by University of Wisconsin, Madison, recorded as terminated on the registry.
Overview
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance is a phase 2 interventional study registered as NCT00582166 by University of Wisconsin, Madison, with 18 participants recorded, started 2005-01-25 and due to reach its primary completion in 2013-03. Interventions recorded: Ibritumomab Tiuxetan (Zevalin) + Rituximab. Conditions recorded: Non-Hodgkin's Lymphoma.
Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialZevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Shares Ibritumomab tiuxetan, Rituximab and the tag pipeline.
- TrialA Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
Shares Ibritumomab tiuxetan and the tag pipeline.
- TrialA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialStudy of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.